

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Douglas Pat Cerretti

Serial No.: -- to be assigned--

Group Art Unit No.: To be assigned

Filed: July 29, 2003

Examiner: To be assigned

For: ADAM20 (SVPH1-26) DNA AND POLYPEPTIDES

Docket No.: 2861-US-A

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, applicants submit a "List of References Cited by Applicant" on a modified PTO-1449 form for consideration by the Examiner.

In accordance with 37 CFR 1.98(d), copies of the patents, publications or other information listed in this information disclosure statement are not required to be provided and are not enclosed because they were previously cited by or submitted to the Office in prior application Serial No. 09/561,779. The present application is a continuation of application Serial No. 09/561,779 which is relied upon for an earlier filing date under 35 USC 120.

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under section 1.114, whichever event occurs last. 37 CFR 1.97(b).

Applicants request consideration of this information and passage of the application to issue.

The Commissioner is hereby authorized to charge any filing fees which may be required or credit any overpayment to Deposit Account No. 09-0089 in the name of Immunex Corporation.

Respectfully submitted,



Please send all future correspondence to:
Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Tel: (206) 587-0430

Suzanne A. Sprunger, Ph.D.
Attorney for Applicant
Registration No.: 41,323
Phone: (206) 265-4071 (direct)
Date: July 29, 2003

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY DOCKET NO. 2861-US-A	SERIAL NO. --to be assigned--		
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		APPLICANT Douglas Pat Cerretti					
		FILING DATE July 29, 2003	GROUP To be assigned				
U.S. PATENT DOCUMENTS							
EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
B1		WO 99/07856	2/18/909	WIPO/PCT			
OTHER DOCUMENTS (<i>Including Author, Title, Date, Pertinent Pages, Etc.</i>)							
	C1	Hillier L, et al., "WashU-Merck EST Project 1997", EMBL/GENBACK/DDBJ databases Accession No. AA400496, Sequence Reference HS 1200798, EMBL Nucleotide Sequence, XP002088620, April 29, 1997. (abstract only)					
	C2	Hillier L, et al., "WashUpMerck EST Project 1997", EMBL/GENBANK/DDBJ databases Accession No. AA400588, Sequence Reference HS 1200890, EMBL Nucleotide Sequence, XP002088620, April 29, 1997. (abstract only)					
	C3	Weskamp G, et al., "MDC9, A widely Expressed Cellular Disintegrin Containing Cytoplasmic SH3 Ligand Domains," <i>The Journal of Cell Biology</i> , 132(4):717-726 (1996).					
	C4	Wolfsberg TG, et al., "ADAM, a Novel Family of Membrane Proteins containing A Disintegrin and Metalloprotease Domain: Multipotential Functions in Cell-Cell and Cell-Matrix Interactions," <i>The Journal of Cell Biology</i> , 131(2):275-278 (1995).					
	C5	Hooft van Huijsduijnen R. "ADAM 20 and 21; Two Novel Human Testis-Specific Membrane Metalloproteases with Similarity to Fertilin- α ," <i>GENE</i> , 206(2):273-282, (1998).					
EXAMINER							
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>							